Navigation Links
A Message to Investors from China Sky One Medical, Inc.
Date:4/21/2009

HARBIN, China, April 21 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC"), today responded to comments made by certain stock analysts, including short selling advisors, regarding the quality of its financial statements and corporate governance. These individuals never had any contact with the management of China Sky One Medical, Inc.

The reports issued by certain short selling advisors specifically called into question the Company's full year basic earnings per share (EPS) figures in its earnings press release dated April 15, 2009. The Company stands by its full year basic earnings per share figures as represented on its April 15, 2009, earnings press release and filed in its Form 10-K. In addition, the reports question the Company's ability to generate consistent gross margin, especially in light of volatile selling prices for certain products. This reports failed to note that overall average selling prices did not exhibit the same level of volatility, due to changes in the Company's diverse mix of 97 products, the growing contribution of new biochemical products and the discontinuation of lower priced contract products.

Finally, the reports issued by the short selling advisors cast doubt on the quality of the Company's corporate governance. The Company meets all corporate governance standards required by the NASDAQ stock market, including a board with a majority of independent directors and the establishment of audit, compensation and corporate governance and nominating committees.

"We have noticed that short selling advisors are disseminating information disparaging the quality of our corporate governance and financial data, and we take this matter very seriously," said Mr. Yan-Qing Liu, Chairman and Chief Executive Officer of China Sky One Medical, Inc. "We stand by the quality of our financial statements and governance, and would like to reiterate that management has not had any contact with the individuals circulating this information. In addition, we encourage all investors to contact us directly, or through CCG Investor Relations, our investor relations firm, for any further clarifications, questions, or concerns, which we will provide in a timely manner."

About China Sky One Medical, Inc.

China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company ("TDR"), Harbin First Bio- Engineering Company Limited ("First"), Heilongjiang Tianlong Pharmaceutical, Inc. ("Tianlong") and Peng Lai Jin Chuang Pharmaceutical Company ("Jin Chuang") the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit http://www.skyonemedical.com .

Safe Harbor Statement

Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward-looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding the CEO's remarks. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.

    For more information, please contact:

    Company Contact:
     China Sky One Medical, Inc.
     Mr. Yu-Bo Hao, CFO
     Tel:   +86-451-5399-4069
     Email: china_sky_one@yahoo.cn

    Investor Relations Contact:
     CCG Investor Relations
     Mr. Crocker Coulson, President
     Tel:   +1-646-213-1915
     Email: crocker.coulson@ccgir.com
     Web:  http://www.ccgirasia.com

'/>"/>
SOURCE China Sky One Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Nurses Send Sutter a Clear Message
2. Message for Activists at Latino National Congreso Convention: Amnesty Will Exacerbate National Problems and Turn the U.S. into Another Mexico
3. Hearing messages embedded in noise could be early sign of schizophrenia
4. Message to the elderly: Its never too late to prevent illness!
5. Classifying indoor tanning behaviors can help physicians tailor prevention messages
6. American Cancer Society President Elmer Huerta Shares Inspirational Message on Azteca Americas Issues: Caras Y Voces
7. Ring Up Instant Nutrition Info via Text Message to DIET1 (34381)
8. Lupus Foundation of America Launches Website Message Boards to Connect People With Lupus
9. His and Hers Screening Campaign Offers Unique Valentines Day Message to Increase Cancer Screenings and Promote Health
10. An Important Message to Anyone Taking Viagra ... From The Women Who Love You ... and Zoller Labs
11. Country Music Star Troy Gentry Partners With National Non-Profit Patient Advocate Foundation to Spread the Message About Challenges to Healthcare Access for Insured and Uninsured Americans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... ... ... The Patient Advocacy Community of The Beryl Institute presented Eve DeVaro, Director, Patient ... Award in recognition of her extraordinary contributions to the field of patient advocacy ... Institute’s annual Patient Experience Conference on March 20 in Denver, Colorado. ...
(Date:4/21/2017)... Hong Kong (PRWEB) , ... April 21, 2017 , ... ... Printing (U3DP), the first 3D printing facility among higher education institutions in Hong Kong ... 3D printing, in terms of the range and quantity of facilities in Hong Kong. ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... AWARE: A Week of Addiction and Recovery Education, from April 24 to April ... preventing substance use disorders. , The mission of AWARE is to instill ...
(Date:4/21/2017)... , ... April 21, 2017 , ... ... announced an exciting new partnership with the highly regarded and well renowned Asian ... highly innovative, myTAP & myTAP PAP Nasal Pillow Mask, and will stabilize and ...
(Date:4/21/2017)... Worcestershire, UK (PRWEB) , ... April 21, 2017 ... ... Award for Enterprise in the category of International Trade, the UK’s most prestigious ... in international trade, which represents 95% of total revenues and has grown by ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017 Research and ... Biosimilar Pipeline and Market Prospects: Addressing Production Complexities Through ... their offering. ... "Global Biosimilar Pipeline and Market Prospects: Overcoming Production ... an in-depth assessment of the current trends in the ...
(Date:4/20/2017)... , April 20, 2017   ZappRx, Inc ., ... specialty drug prescribing process, today announced it closed $25 million ... a venture capital firm based in Seattle ... Qiming Venture Partners . The Series B round included participation ... round in 2014, and GV (formerly Google Ventures). ...
(Date:4/20/2017)... NeuroVive Pharmaceutical AB (Nasdaq Stockholm: ... preclinical results demonstrating anti-fibrotic effects with NV556, ... (NASH), in an additional well-validated experimental NASH ... previously shown similar anti-fibrotic effects in the ... present novel data demonstrating anti-fibrotic effects of ...
Breaking Medicine Technology: